-
April 25, 2013
Eli Lilly has turned in a profit for the first quarter of the year, as cost-cutting measures helped offset a greater investment in R&D.
Full story
-
April 24, 2013
Novartis posts a 7% rise in first-quarter profit and announced new group CFO.
Full story
-
March 14, 2013
The US FTC has filed an amicus (friend of the court) brief with a District Court, pointing out the potential for brand-name drugmakers to "improperly" use restricted drug distribution programmes to impede generic competition.
Full story
-
February 07, 2013
Lundbeck has posted flat revenues and a 28% decline in earnings for the fourth quarter as US generic competition continued to ravage sales of the antidepressant Lexapro
Full story
-
December 20, 2012
Lundbeck's stock took a sharp downturn yesterday (Wednesday) as investors got nervous over news that the firm has cut its financial outlook for the next couple of years.
Full story
-
December 17, 2012
Competition from generics has hampered the US $109.6 billion branded drug manufacturing sector's performance over the last five years, and revenues will fall at an average annual rate of 2.6% during the next few years, a new report forecasts.
Full story
-
November 30, 2012
Minor, non-therapeutic changes to a branded drug product that can harm generic competition can constitute a violation of US antitrust laws, the Federal Trade Commission (FTC) has advised.
Full story
-
July 18, 2012
US drugmakers have been taken aback by an appeal court's decision this week that "pay-for-delay" deals aimed at keeping generic competition off the market are anti-competitive.
Full story
-
June 15, 2012
Lundbeck is cutting around 600 jobs in Europe from its sales forces in response to the tough environment and generic competition to its flagship antidepressant Cipralex/Lexapro
Full story
-
March 14, 2012
Sanofi is to close its manufacturing facility in Newcastle, UK, a move which will see the loss of around 450 jobs
Full story